2,654,944 Shares in Savara Inc (NASDAQ:SVRA) Purchased by Rosalind Advisors Inc.

Rosalind Advisors Inc. purchased a new stake in Savara Inc (NASDAQ:SVRA) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,654,944 shares of the company’s stock, valued at approximately $8,151,000. Savara makes up 4.0% of Rosalind Advisors Inc.’s holdings, making the stock its 9th largest holding.

Other large investors have also recently added to or reduced their stakes in the company. Cibc World Markets Corp acquired a new position in shares of Savara in the 4th quarter worth approximately $33,000. Virtu Financial LLC bought a new position in Savara in the 3rd quarter valued at $67,000. BNP Paribas Financial Markets boosted its stake in Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after purchasing an additional 18,534 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Savara by 14.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after purchasing an additional 4,732 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Savara in the third quarter valued at $174,000. 87.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on SVRA shares. Wells Fargo & Company assumed coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Price Performance

Savara stock opened at $2.82 on Friday. The business’s 50-day simple moving average is $2.73 and its 200 day simple moving average is $3.32. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $483.97 million, a price-to-earnings ratio of -6.56 and a beta of 0.60. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.34.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.